Pcsa stock.

What's Happening With PCSA Stock Today? Processa Pharmaceuticals Inc (PCSA) stock is unchanged 0% while the S&P 500 has risen 0.7% as of 4:00 PM on Friday, Oct 13. PCSA is unchanged $0.00 from the previous closing price of $0.48 on volume of 19,953,405 shares. Over the past year the S&P 500 has risen 18.49% while PCSA has fallen -76.24%.Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304.Find the latest historical data for Processa Pharmaceuticals, Inc. Common Stock (PCSA) at Nasdaq.com.PCSA Nasdaq Stock Market. PCSA Nasdaq Stock Market. PCSA Nasdaq Stock Market. Market closed Market closed. No trades. See on Supercharts. Overview Financials . News . Ideas Technicals Forecast . PCSA news. Time Symbol Headline Provider. Love in every #TradingView. 60M+ Traders and investors use our platform. #1. Top website in the …

About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Processa Pharmaceuticals, Inc. Common Stock (PCSA) Pre ...

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing ...If you want to know the highest single-share unadjusted price, here is your answer. Processa-Pharmaceuticals-Inc's's share attained a price of $35.77 during 10- ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. See Processa Pharmaceuticals, Inc. (PCSA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Processa Pharmaceuticals, Inc. Common Stock (PCSA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Track Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Pdx to nyc

A high-level overview of Processa Pharmaceuticals, Inc. (PCSA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Processa Pharmaceuticals Stock forecast & analyst price target predictions based on 1 analysts offering 12-months price targets for PCSA in the last 3 months. 52 Week High Date 10/16/23. 52 Week Low 1.40. 52 Week Low Date 04/16/24. Market Cap 6.197M. Shares Out 2.86M. 10 Day Average Volume 8.03M. Dividend -. Dividend Yield -. Beta 0.58. PCSA is unchanged $0.00 from the previous closing price of $0.55 on volume of 537,604 shares. Over the past year the S&P 500 has risen 17.03% while PCSA is lower by -70.59%. PCSA lost -$1.44 per share the over the last 12 months. Click Here to get the full Stock Report for Processa Pharmaceuticals Inc stock.PCSA Stock Data Market Cap 7.09M. Float 2.49M. Insiders Ownership 11.27%. Institutions Ownership 1.98%. Short Percent 1.25%. Industry Heavy Duty Truck Manufacturing. Sector Manufacturing. Website Link. Country United States of America. City HANOVER. About PCSA. processa pharmaceuticals was founded in october 2017 with …May 6, 2024 · Rhea-AI Summary. Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has closed a public offering of 1,555,555 shares of common stock and common warrants, raising $7.0 million in gross proceeds. The offering price per share was $4.50, with the common warrants having an exercise price of $4.50 per share and a term of five years. 52 Week High Date 10/16/23. 52 Week Low 1.40. 52 Week Low Date 04/16/24. Market Cap 6.197M. Shares Out 2.86M. 10 Day Average Volume 8.03M. Dividend -. Dividend Yield -. Beta 0.58.Chg %. $2.1700. -0.0900. -3.98%. Processa Pharmaceuticals Inc. advanced stock charts by MarketWatch. View PCSA historial stock data and compare to other stocks and exchanges.

Co-Founder recently bought US$51k worth of stock Feb 10. Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule Feb 07. Processa Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.99989 million. ... PCSA) Cash Burn Rate Jan 20. Processa Pharmaceuticals …©2024 Processa Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy Disclaimer Sitemap Manage Cookie Preferences. Market Data copyright © 2024 QuoteMedia.Data ...You can buy or sell PCSA and other ETFs, options, and stocks. View the real-time PCSA price chart on Robinhood and decide if you want to buy or sell commission-free. Other fees such as trading (non-commission) fees, Gold subscription fees, wire transfer fees, and paper statement fees may apply. See Robinhood Financial’s fee schedule at rbnhd ...Processa Pharmaceuticals ( NASDAQ: PCSA) lost ~16% on Wednesday after the drug developer disclosed feedback it received from the FDA regarding a mid-stage trial for its chemotherapy candidate ...

About. Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica.Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins an...

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference. HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of …A high-level overview of Processa Pharmaceuticals, Inc. (PCSA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Processa Pharmaceuticals stock analysis 2024. View PCSA current price, quote, financial & revenue summaries, forecast, earnings transcripts, and news. ... Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use. Company. About … Processa Pharmaceuticals Stock forecast & analyst price target predictions based on 1 analysts offering 12-months price targets for PCSA in the last 3 months. Processa Pharmaceuticals Stock Forecast, PCSA stock price prediction. Price target in 14 days: 2.886 USD. The best long-term & short-term Processa ...PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer therapeutic. The company has also gotten the regulatory green light to move into a Phase 2 trial for its breast cancer treatment.The stock of Processa Pharmaceuticals Inc (PCSA) has seen a -18.55% decrease in the past week, with a 31.17% gain in the past month, and a -14.04% decrease in the past quarter. The volatility ratio for the week is 10.23%, and the volatility levels for the past 30 days are at 10.65% for PCSA.

Fat dogs

PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ...

Jan 25, 2024 · PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ... Interactive Chart for Processa Pharmaceuticals, Inc. (PCSA), analyze all the data with a huge range of indicators.Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304.Processa Pharmaceuticals, Inc. (PCSA.NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Processa Pharmaceuticals, Inc ...Processa Pharmaceuticals, Inc. Common Stock (PCSA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Processa Pharmaceuticals Inc. is a development-stage pharmaceutical company that uses a unique approach to develop not discover drugs that help in the treatment of oncology and other high unmet medical need diseases with unparalleled regulatory science and clinical expertise. Our drug candidates are intended for patients who have limited ... How much insider buying is happening at Processa Pharmaceuticals? Insiders have purchased a total of 45,600 PCSA shares in the last 24 months for a total of $161,075.00 bought. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ...A high-level overview of Processa Pharmaceuticals, Inc. (PCSA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.N/A. Q2 2024 EPS Estimate Trends. Current. -$0.90. 1 Month Ago. N/A. 3 Months Ago. N/A. Processa Pharmaceuticals Inc. analyst estimates, including PCSA earnings per share estimates and analyst ...The value each PCSA share was expected to gain vs. the value that each PCSA share actually gained.. Processa Pharmaceuticals (PCSA) reported Q1 2023 earnings per share (EPS) of-$3.60, beating estimates of -$5.60 by 35.71%.In the same quarter last year, Processa Pharmaceuticals's earnings per share (EPS) was-$4.Processa …

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces CEO George Ng's corporate overview presentation at the Biotech Showcase 2024, focusing on developing next-gen chemotherapeutic drugs for cancer patients.PCSA. Press Releases Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering. 19d ago. PCSA. Company Announcements Processa Pharmaceuticals Announces Offering Pricing Details. 20d ago. 8K. PCSA. Company Announcements Processa Pharmaceuticals Secures $7M in Public Offering.Processa Pharmaceuticals Inc stock price live, this page displays NASDAQ PCSA stock exchange data. View the PCSA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Processa Pharmaceuticals Inc real time stock price chart below.Processa Pharmaceuticals Inc PCSA shares are trading higher by 36.9% to $0.28 during Friday’s session after the company announced plans to expand the development of Next Generation Capecitabine (“NGC-Cap”) into the treatment of advanced or metastatic breast cancer.. What Else? Following discussions with the FDA, the …Instagram:https://instagram. dallas charlotte flights Find the latest SEC Filings data for Processa Pharmaceuticals, Inc. Common Stock (PCSA) at Nasdaq.com. Processa Pharmaceuticals Inc stock (PCSA) in USD. 1 PCSA = 2.48 USD. 1 month. 6 months. 1 year. 5 years. Processa Pharmaceuticals Inc stock performance at a glance. Check Processa Pharmaceuticals Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. PCSA Stock … flights to cabos san lucas Jan 26, 2024 ... The market value of their outstanding shares is at $4.9 million. Processa Pharma (NASDAQ:PCSA) stock declined by 28.63% to $3.64. The ...As of 1:30 PM EDT. Market Open. HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical ... pa docet HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Dr. David Young ... boise to chicago flights Rhea-AI Summary. Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has closed a public offering of 1,555,555 shares of common stock and common warrants, raising $7.0 million in gross proceeds. The offering price per share was $4.50, with the common warrants having an exercise price of $4.50 per share and a term of five years. arctic treehouse Processa Pharmaceuticals Inc stock (PCSA) in USD. 1 PCSA = 2.48 USD. 1 month. 6 months. 1 year. 5 years. Processa Pharmaceuticals Inc stock performance at a glance. Check Processa Pharmaceuticals Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. PCSA Stock … buffalo a new york Get Processa Pharmaceuticals Inc (PCSA.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... (PCSA.O) Company Information ...3.1900. 3.2900. 3.2900. 23,200. *Close price adjusted for splits. **Close price adjusted for splits and dividend and/or capital gain distributions. Discover historical prices for PCSA stock on Yahoo Finance. View daily, weekly or monthly formats back to when Processa Pharmaceuticals, Inc. stock was issued. play free poker games HANOVER, MD - Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company, has announced a reverse stock split with a ratio of 1-for-20, set to take effect at market open ...PCSA has fallen -$0.02 from the previous closing price of $2.34 on volume of 37,450 shares. Over the past year the S&P 500 has risen 20.23% while PCSA has fallen -85.85%. PCSA lost -$22.82 per share the over the last 12 months. Click Here to get the full Stock Report for Processa Pharmaceuticals Inc stock.Jan 18, 2024 ... Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced a reverse stock split with a fixed split ratio of 1-for-20. The stock will begin trading ... waterbury inn door county Find the latest Processa Pharmaceuticals, Inc. (PCSA) stock quote, history, news and other vital information to help you with your stock trading and investing.HANOVER, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, presented two abstracts at the American Association for Cancer … where to watch gifted movie PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer therapeutic. The company has also gotten the regulatory green light to move into a Phase 2 trial for its breast cancer treatment. phone number for hughesnet Track Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors PCSA has fallen -$0.02 from the previous closing price of $2.34 on volume of 37,450 shares. Over the past year the S&P 500 has risen 20.23% while PCSA has fallen -85.85%. PCSA lost -$22.82 per share the over the last 12 months. Click Here to get the full Stock Report for Processa Pharmaceuticals Inc stock. graffiti marker PCS3117 for Pancreatic Cancer. On June 17, 2021, we entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs. Rx-3117 has a family of patents extending into 2036 as well as ...Processa Pharmaceuticals, Inc. Common Stock (PCSA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules. (GlobeNewswire) Jan-04-23 08:30AM. Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.